ArticleJournal of gastrointestinal oncology2025
Survival analysis of small cell carcinoma of the esophagus: a 15-year retrospective study from a high-incidence region.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell carcinoma of the esophagus (SCCE) is a rare malignant carcinoma, which is highly aggressive and prone to recurrence and metastasis. There is no standard therapeutic modality for SCCE. We aimed to describe the clinical characteristics and therapeutic outcomes of SCCE, analyse its prognostic factors, and provide a reference for establishing a standard treatment regimen. Methods: We retrospectively evaluated 156 consecutive patients with SCCE, who received treatment at Fujian Cancer Hospital between 2007 and 2022. We finally included 140 patients in the analysis. The primary endpoint was overall survival (OS); the key secondary endpoint was progression-free survival (PFS). Multivariate Cox regression survival analysis was conducted to identify the independent prognostic factors. Subgroup analysis included treatment modalities used to patients with limited stage SCCE (LS-SCCE). Results: The median OS was 24.0 [95% confidence interval (CI): 19.391-28.609] months and the 1-, 3-, and 5-year OS rates were 79.3%, 20.0%, and 9.3%, respectively. The multivariate Cox analysis suggested that chemotherapy was an independent prognostic factor [hazard ratio (HR) 0.519; 95% CI: 0.271-0.992; P=0.047]. In subgroup analysis for patients with LS-SCCE, the median OS was 26 months for patients receiving surgery-based multimodal therapy [surgery (S) ± chemotherapy (CT) ± radiotherapy (RT)] compared to 31 months for those receiving definitive chemoradiotherapy (CRT) (P=0.97). There was no significant difference between the two groups. Conclusions: Our results suggest that CRT might be an effective first-line treatment for LS-SCCE and is not inferior to surgery. The conclusions are expected to provide a reference for the standardised treatment of SCCE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.